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Abstract
Background: To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone
immediate-release using propensity score methodology.
Methods: Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with
availability of individual patient-level data were identified (3 per compound). Propensity score pairwise matching
was used to balance observed covariates between the paliperidone ER and risperidone patient populations. Scores
were generated using logistic regression models, with age, body mass index, race, sex, baseline Positive and
Negative Syndrome Scale (PANSS) total score and baseline Clinical Global Impressions–Severity (CGI-S) score as
factors. The dosage range of paliperidone ER (6-12 mg/day) was compared with 2 risperidone dosage ranges:
2-4 and 4-6 mg/day. The primary efficacy measure was change in PANSS total score at week 6 end point.
Tolerability end points included adverse event (AE) reports and weight. AEs with rates ≥5% and with a ≥2%
difference between paliperidone ER and risperidone were identified.
Results: Completion rates for placebo-treated subjects in paliperidone ER trials (n = 95) and risperidone trials (n =
122) groups were 36.8% and 51.6%, respectively; end point changes on PANSS total scores were similar (p = 0.768).
Completion rates for subjects receiving paliperidone ER 6-12 mg/day (n = 179), risperidone 2-4 mg/day (n = 113)
or risperidone 4-6 mg/day (n = 129) were 64.8%, 54.0% and 66.7%, respectively (placebo-adjusted rates:
paliperidone ER vs risperidone 2-4 mg/day, p = 0.005; paliperidone ER vs risperidone 4-6 mg/day, p = 0.159).
PANSS total score improvement with paliperidone ER was greater than with risperidone 2-4 mg/day (difference in
mean change score, -6.7; p < 0.05) and similar to risperidone 4-6 mg/day (0.2; p = 0.927). Placebo-adjusted AEs
more common with paliperidone ER were insomnia, sinus tachycardia and tachycardia; more common with
risperidone were somnolence, restlessness, nausea, anxiety, salivary hypersecretion, akathisia, dizziness and nasal
congestion. Weight changes with paliperidone ER and risperidone were similar (paliperidone ER vs risperidone
2-4 mg/day, p = 0.489; paliperidone ER vs risperidone 4-6 mg/day, p = 0.236).
Conclusions: This indirect database analysis suggested that paliperidone ER 6-12 mg/day may be more efficacious
than risperidone 2-4 mg/day and as efficacious as risperidone 4-6 mg/day. The AE-adjusted incidence rates suggest
differences between treatments that may be relevant for individual patients. Additional randomized, direct, head-
to-head clinical trials are needed to confirm these findings.
Background
Paliperidone extended-release (ER) is an atypical anti-
psychotic that delivers the active metabolite of risperi-
done (9-hydroxyrisperidone) using OROS
® technology.
This formulation minimizes drug plasma fluctuations
relative to oral immediate-release risperidone and
eliminates the need for initial dose titration [1,2]. The 2
drugs also differ in that risperidone is metabolized in
the liver via the cytochrome (CYP) P450 2D6 pathway,
whereas this pathway is minimally involved in the meta-
bolism of paliperidone ER. Therefore, the potential for
clinically significant interactions between paliperidone
ER and other drugs metabolized by the CYP P450 2D6
pathway may be minimal [3,4].
The efficacy and safety of risperidone for the treatment
of schizophrenia were established more than 15 years ago
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any medium, provided the original work is properly cited.[5,6]. More recently, multinational placebo-controlled stu-
dies have shown paliperidone ER 3-15 mg/day to be both
efficacious and safe, with discontinuation rates due to
adverse events (AEs) similar to placebo [7-9]. To date,
and to our best knowledge, however, no studies have
been specifically designed to directly compare the efficacy
of paliperidone ER and oral risperidone.
The objective of the current analysis was to perform a
post hoc statistical indirect comparison of paliperidone
ER and risperidone using propensity score matching.
Propensity scores, originally introduced by Rosenbaum
and Rubin [10], can be used to create treatment groups
that are balanced on a large number of baseline charac-
teristics; they are the observational study analogue of
randomization.
Methods
Analysis sets
This comparative analysis pooled double-blind, rando-
mized, placebo-controlled, short-term (4- to 8-week)
clinical studies of paliperidone ER or risperidone mono-
therapy in acutely ill adults with schizophrenia aged
18-65 inclusive, in which detailed patient-level data were
available. A total of 6 studies were identified: 3 for pali-
peridone ER and 3 for risperidone (Table 1). A literature
search (through December 31, 2009) confirmed that
these 6 studies were the only studies that met the inclu-
sion criteria and had individual patient-level data that
were available. In the risperidone studies (conducted
between 1988 and 1996), prior antipsychotic treatment
consisted primarily of conventional agents, whereas in
the paliperidone ER studies (conducted between 2004
and 2005), over 50% of subjects had received prior treat-
ment with atypical antipsychotics. Therefore, subjects
f r o mt h ep a l i p e r i d o n eE Rt r i a l sw e r ei n c l u d e do n l yi f
they had received conventional antipsychotics within
90 days before the start of the study, regardless of con-
comitant use of other agents, including atypical antipsy-
chotics. All subjects in risperidone studies RIS-USA-1
and RIS-INT-3 were included, and RIS-USA-72 subjects
were included if they did not take atypical antipsychotics
prior to the study (clozapine and risperidone were avail-
able at the time of this study). DSM-III-R/IV diagnosis
codes for inclusion were 295.10, 295.20, 295.30, 295.60
or 295.90. Exclusions were age >65 years and risperi-
done >8 mg/day. Because the RIS-USA-1 trial had a
flexible-dosing regimen, subjects were assigned to a
dose group based on their modal dose. Defined treat-
ment groups were paliperidone ER 6-12 mg/day, risperi-
done 2-4 mg/day, risperidone 4-6 mg/day or placebo.
Since the studies were conducted during different dec-
ades, the above inclusion and exclusion criteria for this
analysis were chosen to minimize differences between
the populations.
Paliperidone ER in the dose range 6-12 mg/day was
chosen for comparison because it is likely to provide a
favorable risk/benefit for most patients with schizophre-
nia. (The recommended range is 3-12 mg/day.) Based
on pharmacokinetic data, paliperidone 6-12 mg/day and
risperidone 2-4 mg/day were compared because they
were expected to provide similar systemic drug exposure
[2]. Paliperidone ER 6-12 mg/day was also compared
with risperidone 4-6 mg/day as these dose ranges were
expected to yield the most favorable risk/benefit ratios
based on clinical data. The placebo groups of the risper-
idone and paliperidone ER trials were referred to as
placebo (risperidone [RIS]) and placebo (paliperidone
ER [PALI]). They were pooled for some analyses as
described below.
Efficacy and safety outcomes
Efficacy endpoints included change in the Positive and
Negative Syndrome Scale (PANSS) total (primary effi-
cacy measure) [11] and factor scores [12] (for all studies
excluding RIS-USA-1), Clinical Global Impressions-
Severity (CGI-S) score [13] (for all studies excluding
RIS-USA-72), response rates (≥30% decrease in total
PANSS score from baseline), weight and spontaneously
reported AEs. Owing to differences in AE coding
between programs, 2 clinicians reviewed all AEs in a
blinded fashion to map verbatim terms to preferred
terms; these were then mapped to a System Organ Class
(SOC) using MedDRA (Medical Dictionary for Regula-
tory Activities) terminology. Extrapyramidal symptoms
(EPS) measures were not included due to the difference
in rating scales between the risperidone (Extrapyramidal
Symptoms Rating Scale) and paliperidone (Simpson
Angus Scale) studies.
Statistical analysis
Propensity score matching
In the present analysis, propensity score matching was
used to create comparison groups that were similar with
respect to the distribution of a number of demographic
and baseline characteristics so that indirect comparisons
would be more valid. A propensity score for each
patient was created using variables common to both sets
of studies from multiple logistic regression models. Sub-
jects were matched as strin g e n t l ya sp o s s i b l ew h i l e
maintaining sufficient patient numbers for analysis. A 1-
to-many matching scheme with a caliper (distance) of
0.05 was used to match each treated subject with the
closest control. In 1-to-many matching, all cases are
initially matched to their “best” control in the first itera-
tion, and “next best” matches next in hierarchical
sequence until no more matches can be made. Best
matches are those with the smallest difference in pro-
pensity scores. Goodness of matches and available
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algorithm used to create a new analysis population.
Based on the selected population of 933 subjects from
6 placebo-controlled trials, matched cohorts were cre-
ated by 1) pairing risperidone (regardless of dose) and
its corresponding placebo group (placebo [RIS]) and 2)
pairing paliperidone ER (regardless of dose) and its cor-
responding placebo group (placebo [PALI]). This was
followed by pairing from the resulting risperidone and
paliperidone ER groups identified in steps 1 and 2. All
subjects in the matched risperidone/paliperidone ER
group were included in the final sample. The placebo
groups identified in the pairing with risperidone or pali-
peridone ER were then compared to confirm whether
they could be combined into a pooled placebo group for
efficacy analyses. This provided 3 groups (risperidone,
paliperidone ER and placebo) for the efficacy
comparisons. The dependent variable of the multiple
logistic regression models was treatment group, and the
independent variables were age, sex, race (white vs all
other), baseline body mass index (BMI), baseline CGI
and baseline PANSS. Choice of the independent vari-
ables was based on clinical relevance and their inclusion
in all 6 studies.
Analysis methods
The primary comparisons were between paliperidone ER
6-12 mg/day and each dose range of risperidone. Changes
from baseline to end point (week 4 in RIS-USA-72, week
8 in RIS-INT-3 and week 6 for all other studies) were
evaluated using the last-observation-carried-forward
(LOCF) approach. Comparisons were calculated from
analysis-of-covariance models, with treatment as the
between group factor and baseline as the covariate. Cate-
gorical variables and response rates at end point were
Table 1 Randomized placebo-controlled studies available for analysis
Paliperidone ER
Study
(Year
Completed)
N* Population Dose (mg/day) Duration
(Weeks)
Efficacy
Measures
Safety Measures
PALI-SCH-303
(2005) [7]
500
† ￿ Patients with schizophrenia, diagnosis for ≥1y r
￿ Agreed to hospitalization for at least the first 14
days of the study
￿ Acute episode with PANSS total score 70-120
6, 9, 12 (qd) 6 PANSS, CGI SAS, BARS, AIMS,
AEs, labs, weight
PALI-SCH-304
(2004) [8]
327
† ￿ Patients with schizophrenia, diagnosis for ≥1y r
￿ Agreed to hospitalization for at least the first 14
days of the study
￿ Acute episode with PANSS total score 70-120
6, 12 (qd) 6 PANSS, CGI SAS, BARS, AIMS,
AEs, labs, weight
PALI-SCH-305
(2005)
[9]
366
† ￿ Patients with schizophrenia, diagnosis for ≥1y r
￿ Agreed to hospitalization for at least the first 14
days of the study
￿ Acute episode with PANSS total score 70-120
3, 9, 15 (qd) 6 PANSS, CGI SAS, BARS, AIMS,
AEs, labs, weight
Risperidone
Study N Population Dose (mg/day) Duration
(Weeks)
Efficacy
Measures
Safety Measures
RIS-USA-1 (1990)
‡ 160 ￿ Patients with schizophrenia
￿ Inpatients at the start of the study
￿ Minimum BPRS score of 30, with a minimum
score of at least moderate (4) on 2 of the
following items: conceptual disorganization,
suspiciousness, hallucinatory behavior, unusual
thought content
1-10
§ (qd) 6 BPRS, CGI ESRS, AIMS, AEs,
labs, weight
RIS-INT-3 (1991)
[5]; [6]
523 ￿ Patients with chronic schizophrenia
￿ Inpatients at the start of the study
￿ PANSS total score 60-120
2, 6, 10,16 (bid) 8 PANSS, CGI ESRS, AEs, labs,
weight
RIS-USA-72 (1996)
‡ 246 ￿ Patients with schizophrenia
￿ Inpatients at the start of the study
￿ PANSS total score 80-120, with a PANSS score
≥8 for the sum of 2 of the following items:
conceptual disorganization, suspiciousness,
hallucinatory behavior, unusual thought content
4, 8 (qd) 4 PANSS ESRS, AEs, labs,
weight
*Intent-to-treat population.
†N values represent subjects who received the recommend dose of paliperidone ER (3-12 mg/day) or placebo.
‡Data on file.
§Flexible dosing.
PANSS = Positive and Negative Syndrome Scale; CGI = Clinical Global Impressions; SAS = Simpson-Angus Scale; BARS = Barnes Akathisia Rating Scale; AIMS=
Abnormal Involuntary Movement Scale; AEs = adverse events; BPRS = Brief Psychiatric Rating Scale; ESRS = Extrapyramidal Symptoms Rating Scale.
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multiple comparisons were made. Data were analyzed
using SAS
® (Version 9.1 for Windows).
Differences between placebo groups were examined,
and placebo-adjusted rates were reported for those that
were significant (as was the case for completion and AE
rates). For adjusting AE rates, placebo corrections were
applied to each active group (ie, active % – corresponding
placebo %) according to the equation: ([risperidone % –
placebo (RIS) %] – [paliperidone ER % – placebo (PALI)
%]). If the placebo rate for any AE was higher than for
active treatment, active treatment minus placebo was set
equal to 0. Differences in AEs between paliperidone ER
and risperidone were noted when the AE differential was
≥2% after correcting for the placebo rates.
Results
Data were available from 2626 subjects in the 6 studies;
of these, 933 subjects were retained in the propensity
score-matched population (Figure 1). A total of 179 sub-
jects received paliperidone ER 6-12 mg/day, 113 subjects
received risperidone 2-4 mg/day, 129 subjects received
risperidone 4-6 mg/day, 95 received placebo in
paliperidone studies (placebo [PALI]) and 122 received
placebo in risperidone studies (placebo [RIS]). Study
completion rates for the 2 placebo groups were 36.8%
with placebo (PALI) and 51.6% with placebo (RIS) (p =
0.030) (Figure 1). Risperidone subjects receiving 4 mg/day
(n = 63) were included in both risperidone groups. A
comparison of the placebo (PALI) and placebo (RIS)
groups for the purposes of validating the selection criteria
used to match the populations indicated that baseline
demographic and clinical characteristics, and between-
group differences at end point on PANSS total and factor
change scores (all p values > 0.05), were similar (Table 2).
Therefore, the placebo groups were pooled (n = 217) for
further efficacy analyses.
Comparison of paliperidone ER and risperidone groups
Baseline demographic and clinical characteristics in the
paliperidone ER and risperidone dose groups were com-
parable, as expected, because of propensity score matching
(Table 3). Completion rates were 64.8% with paliperidone
ER 6-12 mg/day, 54.0% with risperidone 2-4 mg/day and
66.7% with risperidone 4-6 mg/day. Placebo-adjusted rates
were 28.0%, 2.4% and 15.1% in the paliperidone ER,
TOTAL N = 2626
Paliperidone ER studies, n =1697
Risperidone studies, n = 929 
Excluded:
Excluded doses, active comparators*, n = 1040
No conventional antipsychotic ≤90 days, n = 653
N = 933
Paliperidone ER studies, n = 434
Risperidone studies, n = 499
Propensity score matched
N = 575
Paliperidone ER
6-12 mg/day
n = 179
Completed: 64.8%
Discontinued
•Lack of efficacy: 17.3%
•Withdrew consent: 8.4%
•Adverse event: 6.7%
•Lost to follow up: 0.6%
•Noncompliance: 0.6%
•Other: 1.7%
Risperidone
2-4 mg/day
n = 113†
Completed: 54.0%
Discontinued
•Lack of efficacy: 23.9%
•Withdrew consent: 12.4%
•Adverse event: 6.2%
•Lost to follow up: 0.9%
•Noncompliance: 2.7%
•Other: 0
Risperidone
4-6 mg/day
n = 129†
Completed: 66.7%
Discontinued
•Lack of efficacy: 10.9%
•Withdrew consent: 9.3%
•Adverse event: 8.5%
•Lost to follow up: 1.6%
•Noncompliance: 2.3%
•Other: 0.8%
Placebo (PALI)
n = 95
Completed: 36.8%
Discontinued
•Lack of efficacy: 43.2%
•Withdrew consent: 10.5%
•Adverse event: 5.3%
•Lost to follow up: 2.1%
•Noncompliance: 0
•Other: 2.1%
Placebo (RIS)
n = 122
Completed: 51.6%
Discontinued
•Lack of efficacy: 29.5%
•Withdrew consent: 1.6%
•Adverse event: 4.9%
•Lost to follow up: 1.6%
•Noncompliance: 4.9%
•Other: 2.5%
Figure 1 Patient flow and disposition. *Subjects who received haloperidol, olanzapine, risperidone >8 mg/day or an unspecified risperidone
dose, paliperidone ER 3 or 15 mg/day.
†Subjects who received risperidone 4 mg/day (n = 63) were included in both risperidone groups.
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groups, respectively (placebo-adjusted p values for paliper-
idone ER vs risperidone 2-4 mg/day, p = 0.005; paliperi-
done ER vs risperidone 4-6 mg/day, p = 0.159) (Figure 1).
Comparison of paliperidone ER 6-12 mg/day and
risperidone 2-4 mg/day
Paliperidone ER showed greater improvement at end
point on the mean PANSS total score compared with
risperidone 2-4 mg/day (difference in mean change
score, -6.7; p < 0.05), and more improvement on the
PANSS factor scores for negative symptoms (difference
in mean change score, -2.1; p < 0.05) (Table 4). Paliperi-
done ER, but not risperidone 2-4 mg/day, was superior
to combined placebo on the PANSS total score and fac-
tor scores for negative symptoms, anxiety/depression
and disorganized thoughts (p < 0.05 for all comparisons
of paliperidone ER vs placebo). A similar pattern was
observed with the CGI-S score; improvement was
greater with paliperidone ERt h a nr i s p e r i d o n e2 - 4m g /
day (p < 0.001) or combined placebo, but not with ris-
peridone 2-4 mg/day vs combined placebo (Table 4).
The percentage of subjects who achieved a response
(≥30% decrease in total PANSS score from baseline) was
55.1% with paliperidone ER vs 40.7% with risperidone
2-4 mg/day (p < 0.05). Response rates with paliperidone
ER and risperidone 2-4 mg/day were both significantly
higher than with combined placebo (Table 4).
Comparison of paliperidone ER 6-12 mg/day and
risperidone 4-6 mg/day
Changes in mean PANSS total score and all factor
scores did not differ significantly (all between-group p
values > 0.05); both paliperidone ER and risperidone 4-6
mg/day were superior to combined placebo on these
measures (all p values vs placebo < 0.05). Improvement
on the CGI-S scale was greater with paliperidone ER
than risperidone 4-6 mg/day (p < 0.05); paliperidone ER,
but not risperidone 4-6 mg/day, was superior to com-
bined placebo (p < 0.001). Response rates with paliperi-
done ER and risperidone 4-6 mg/day were comparable,
and rates with both active treatments were higher than
Table 2 Baseline parameters and efficacy outcomes in
placebo groups from paliperidone ER and risperidone
studies
Baseline Demographic and Clinical
Characteristics
Placebo
(PALI)
n=9 5
Placebo
(RIS)
n = 122
p
Value
Age, years, mean (SD) 36.7
(10.9)
38.0
(10.1)
0.338
Female, n (%) 23
(24.2)
18
(14.8)
0.083
Race, n (%)
Caucasian 65
(91.6)
73
(93.6)
0.758
Other 6 (8.5) 5 (6.4)
BMI, mean (SD), kg/m
2 24.9
(5.2)
25.3
(3.2)
0.538
PANSS total score, mean (SD) 94.5
(12.2)
92.6
(12.3)
0.254
CGI-S, score (SD) 4.6 (0.7) 4.7 (0.8) 0.105
PANSS, Adjusted Mean Change (SE)
at End Point
Placebo
(PALI)
n=9 2
Placebo
(RIS)
n=9 4
p
Value
Total score -6.5 (2.5) -5.4 (2.5) 0.768
Factor score
Negative -1.3 (0.7) -2.3 (0.7) 0.280
Positive -2.5 (0.8) -1.6 (0.8) 0.423
Anxiety/depression -1.3 (0.4) -1.8 (0.4) 0.402
Disorganized thoughts -1.2 (0.6) -0.6 (0.6) 0.507
Uncontrolled hostility/excitement 0.4 (0.5) 0.9 (0.5) 0.530
PALI = paliperidone ER; RIS = risperidone; BMI = body mass index; PANSS =
Positive and Negative Syndrome Scale; CGI-S = Clinical Global Impressions—
Severity.
p values are from ANOVA models with factor treatment for continuous
variables and chi-square test for categorical variables.
Table 3 Baseline characteristics in the propensity score-matched paliperidone ER, risperidone and pooled placebo
groups
Paliperidone ER
6-12 mg/day
n = 179
Risperidone
2-4 mg/day
n = 113
Risperidone
4-6 mg/day
n = 129
Pooled Placebo
n = 217
Age, years, mean (SD) 37.4 (11.3) 37.8 (10.6) 37.1 (10.1) 37.4 (10.4)
Female, n (%) 45 (25.1) 31 (27.4) 32 (24.8) 41 (18.9)
Race, n (%)
Caucasian 136 (76.0) 83 (73.5) 99 (76.7) 138 (63.6)
Other 43 (24.0) 30 (26.5) 30 (23.3) 79 (36.4)
BMI, mean (SD), kg/m
2 25.2 (4.7) 25.5 (3.3) 25.5 (3.4) 25.1 (4.2)
PANSS total score, mean (SD) 94.3 (11.9) 94.4 (15.2) 96.2 (16.6) 93.4 (12.2)
CGI-S score, mean (SD) 4.8 (0.7) 4.8 (0.6) 4.8 (0.7) 4.7 (0.8)
BMI = body mass index; PANSS = Positive and Negative Syndrome Scale; CGI-S = Clinical Global Impressions—Severity.
All the p values are >0.05 for the group comparisons. p values are from ANOVA models with factor treatment for continuous variables and chi-square test for
categorical variables.
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Paliperidone ER
6-12 mg/day
n = 179
Risperidone
2-4 mg/day
n = 113
Risperidone
4-6 mg/day
n = 126*
Pooled Placebo
n = 186*
PANSS
Total score, adjusted mean change (SE) -18.4 (1.7) -11.6 (2.2) -18.7 (2.0) -6.4 (1.7)
Mean difference (estimated SE)
†
Active-PBO -12.0 (2.4)
‡ -5.4 (2.8) -12.0 (2.6)
‡ NA
PALI-RIS 2-4 mg -6.7 (2.8)
§ NA NA NA
PALI-RIS 4-6 mg 0.2 (2.6) NA NA NA
Negative factor, adjusted mean change (SE) -4.7 (0.5) -2.5 (0.6) -3.8 (0.5) -2.1 (0.4)
Mean difference (estimated SE)
†
Active-PBO -2.6 (0.6)
‡ -0.5 (0.8) -1.7 (0.7)
§ NA
PALI-RIS 2-4 mg -2.1 (0.8)
§ NA NA NA
PALI-RIS 4-6 mg -0.9 (0.7) NA NA NA
Positive factor, adjusted mean change (SE) -6.2 (0.5) -4.5 (0.7) -6.3 (0.7) -2.3 (0.5)
Mean difference (estimated SE)
†
Active-PBO -4.0 (0.8)
‡ -2.2 (0.9)
§ -4.1 (0.8)
‡ NA
PALI-RIS 2-4 mg -1.7 (0.9) NA NA NA
PALI-RIS 4-6 mg 0.1 (0.8) NA NA NA
Anxiety/depression, adjusted mean change (SE) -2.3 (0.3) -1.7 (0.3) -2.5 (0.3) -1.4 (0.3)
Mean difference (estimated SE)
†
Active-PBO -0.9 (0.4)
§ -0.3 (0.4) -1.1 (0.4)
§ NA
PALI-RIS 2-4 mg -0.6 (0.4) NA NA NA
PALI-RIS 4-6 mg 0.2 (0.4) NA NA NA
Disorganized thoughts, adjusted mean change (SE) -3.5 (0.4) -2.3 (0.5) -4.2 (0.5) -1.1 (0.4)
Mean difference (estimated SE)
†
Active-PBO -2.4 (0.6)
‡ -1.3 (0.7) -3.2 (0.7)
‡ NA
PALI-RIS 2-4 mg -1.1 (0.7) NA NA NA
PALI-RIS 4-6 mg 0.8 (0.7) NA NA NA
Uncontrolled hostility/excitement, adjusted mean change (SE) -1.4 (0.3) -0.6 (0.4) -2.0 (0.4) 0.6 (0.3)
Mean difference (estimated SE)
†
Active-PBO -2.0 (0.5)
‡ -1.2 (0.5)
§ 2.6 (0.5)
‡ NA
PALI-RIS 2-4 mg -0.8 (0.5) NA NA NA
PALI-RIS 4-6 mg 0.6 (0.5) NA NA NA
CGI-S, adjusted mean change (SE)
¶ -0.9 (0.1) 0.0 (0.2) -0.1 (0.2) -0.2 (0.1)
Mean difference (estimated SE)
†
Active-PBO -0.7 (0.1)
‡ 0.2 (0.2) 0.0 (0.3) NA
PALI-RIS 2-4 mg -0.9 (0.2)
‡ NA NA NA
PALI-RIS 4-6 mg -0.8 (0.3)
§ NA NA NA
Response, %
# 55.1 40.7 51.6 28.1
Active-PBO 26.9
§ 28.5
§ 23.4
§ NA
PALI-RIS 2-4 mg 14.4
§ NA NA NA
PALI-RIS 4-6 mg 3.5 NA NA NA
Separate models were run for comparison of risperidone 2-4 mg/day and risperidone 4-6 mg/day against paliperidone ER 6-12 mg/day and pooled placebo
groups. Adjusted means for the pooled placebo group are presented from the model comparing paliperidone ER with risperidone 4-6 mg/day. Data are nearly
identical to those for the model comparing paliperidone ER with risperidone 2-4 mg/day. p values are from ANCOVA models with factor treatment and covariate
baseline score for continuous variables and chi-square test for categorical variables.
*Not all subjects had a PANSS assessment.
†A negative sign indicates greater improvement vs comparator.
‡p < 0.0001;
§p < 0.05.
¶Numbers of subjects assessed were 179, 53, 69 and 167 for the paliperidone ER, risperidone 2-4 mg/day, risperidone 4-6 mg/day and pooled placebo groups,
respectively.
#Response was defined as ≥30% decrease in total PANSS score from baseline.
PANSS = Positive and Negative Syndrome Scale; PALI = paliperidone ER; RIS = risperidone PBO = placebo; CGI-S = Clinical Global Impressions—Severity; NA = not
applicable.
Turkoz et al. BMC Psychiatry 2011, 11:21
http://www.biomedcentral.com/1471-244X/11/21
Page 6 of 10with combined placebo (p < 0.001 for both active treat-
ments vs combined placebo) (Table 4).
Safety
No statistical tests were applied to AE data, but placebo
corrections were applied to each active group as
described in the Methods section. Placebo-adjusted AE
rates that differed by ≥ 2% between groups are pre-
sented (Table 5). For the paliperidone ER vs risperidone
2-4 mg comparison, placebo-adjusted AEs more com-
mon with paliperidone ER than risperidone were sinus
tachycardia and tachycardia; placebo-adjusted AEs more
common with risperidone than paliperidone ER were
somnolence, restlessness, nausea, anxiety, salivary hyper-
secretion and akathisia (Table 5). For paliperidone ER vs
risperidone 4-6 mg, placebo-adjusted AEs more com-
mon with paliperidone ER than risperidone included
insomnia and sinus tachycardia; placebo-adjusted AEs
more common with risperidone than paliperidone ER
were somnolence, restlessness, nausea, anxiety, salivary
hypersecretion, akathisia, nasal congestion and dizziness
(Table 5).
Weight change was significantly greater with paliperi-
done ER, risperidone 2-4 mg/day and risperidone 4-6 mg/
day than with placebo (all p values < 0.001), but was not
significantly different among the active-treatment groups.
Adjusted mean change (SE): paliperidone ER, 0.7 (0.3) kg;
risperidone 2-4 mg/day, 1.0 (0.4) kg; and risperidone
4-6 mg/day, 1.3 (0.4) kg (paliperidone ER vs risperidone
2-4 mg/day, p = 0.487; vs risperidone 4-6 mg/day, p = 0.235).
Discussion
This analysis used propensity score matching of subjects
from randomized placebo-controlled schizophrenia stu-
dies to compare paliperidone ER 6-12 mg/day with ris-
peridone 2-4 mg/day and risperidone 4-6 mg/day.
Although the approved dose range of paliperidone ER is
3-12 mg/day, this analysis focused on 6-12 mg/day
because comparisons between paliperidone ER 6-12 mg/
day and risperidone 2-4 mg/day were expected to pro-
vide similar systemic drug exposure based on pharmaco-
kinetic data [2]. Comparisons between paliperidone ER
6-12 mg/day and risperidone 4-6 mg/day were per-
formed as these dose ranges were expected to yield the
most favorable risk/benefit ratios based on clinical data.
The significant difference in the mean PANSS total
scores suggested that paliperidone ER 6-12 mg/day may
be more efficacious than risperidone 2-4 mg/day. Con-
sistent results were observed on PANSS factor scores,
CGI-S scores, response rates and placebo-corrected dis-
continuation rates for lack of efficacy. Data further sug-
gested that paliperidone ER 6-12 mg/day achieved good
overall tolerability compared with risperidone 2-4 mg/
day, except for increased rates for tachycardia and sinus
tachycardia. Discontinuation rates due to AEs were
comparable, and weight gain for the 2 groups was
similar.
Changes in the mean PANSS total score suggested
that paliperidone ER 6-12 mg/day may be similar to ris-
peridone 4-6 mg/day in terms of efficacy. This result is
consistent with PANSS factor score and response rate
data; however, overall clinical status (CGI-S) improved
significantly more with paliperidone ER. Also, these data
suggest that with the exception of increased rates of
insomnia and tachycardia, paliperidone ER 6-12 mg/day
achieved good overall tolerability compared with risperi-
done 4-6 mg/day.
Because there is no control over treatment assign-
ments, covariate differences between groups may lead
to biased estimates of treatment effects, as treatment
groups may not be comparable. The advantage of pro-
pensity score matching is that observed covariates
between groups can be balanced, thereby reducing
selection bias for treatment assignment [14]. Further,
this analysis used individual rather than group data,
offering advantages over meta-analytic techniques such
as the ability to identify the exact populations to be
studied and to have access to individual data points.
Notably, although studies were conducted at different
times and in different countries, no significant differ-
ences were found in baseline-to-end point change on
any efficacy measure between the placebo groups from
the paliperidone ER and risperidone studies, suggesting
that identification of analysis populations using this
approach was viable for comparing paliperidone ER
and risperidone.
However, propensity score analyses have several lim-
itations. First, because this analysis relies on clinical trial
databases, differences in trial design between the
paliperidone ER and risperidone studies may have intro-
duced additional bias in estimating treatment differ-
ences. The shorter duration of RIS-USA-72 (4 weeks vs
6-8 weeks for all other studies) (Table 1) could have
introduced a bias favoring risperidone, particularly with
regard to completion rates and AE reports. Further,
entry into open-label extensions of the paliperidone ER
studies was permitted at week 3; in the RIS-INT-3 ris-
peridone study, however, subjects could enter the open-
label extension only if they completed the double-blind
phase. This difference could have introduced a bias for
completing the risperidone study. At the time the risper-
idone studies were conducted, regulations limited inclu-
sion of women in phase III clinical trials, resulting in
marked differences in the percentages of women
included in the risperidone and paliperidone studies.
Additionally, as patient-level data are necessary to per-
form propensity score analyses, this method can only be
used if individual patient-level data are available.
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identified 4 additional placebo-controlled studies of pali-
peridone ER monotherapy and 5 additional placebo-
controlled studies of risperidone monotherapy that were
not included in the present analysis. Individual patient-
level data were available for the 4 paliperidone ER stu-
dies and for 1 of the risperidone studies, but their
designs were inappropriate for inclusion. The study by
Tzimos et al examined subjects that were >65 years old
[15]. The study by Luthringer et al was 2 weeks in dura-
tion and focused on the effect of paliperidone ER on
sleep measurements [16]. The study by Kramer et al
focused on relapse preventio n ;i ti n c l u d e ds u b j e c t sw h o
were initially stabilized on paliperidone ER for 8 weeks
prior to the double-blind phase [17]. The paliperidone
E Rs t u d yb yC a n u s oe ta la n dt h er i s p e r i d o n es t u d yb y
Potkin et al evaluated monotherapy for only 2 weeks,
followed by a 4-week additive therapy phase during
which additional psychotropics could be administered
[18,19]. For the remaining risperidone studies [20-23],
individual patient-level data for the propensity score
analysis were not available.
Because the propensity score matching approach does
not include all of the subjects from the original studies,
differences can arise in the patient populations. The
nonrandomized design of this study can limit the clini-
cal interpretation of these results. One example is the
significant difference in placebo completion rates—
36.8% for the placebo (PALI) group vs 51.6% for the
placebo (RIS) group—which influenced the placebo-
adjusted response rate of the risperidone groups. Addi-
tionally, the risperidone 2-4 mg/day did not separate
from placebo on PANSS total score change and there-
fore may not have been a valid active risperidone com-
parison for paliperidone ER 6-12 mg/day. However, the
original risperidone study found that the 2 mg/day dose
was superior to placebo [12]. In fact, the p value (0.052)
in this analysis only narrowly missed statistical signifi-
cance. As a result, the significant differences in PANSS
total scores between the paliperidone ER 6-12 mg/day
and risperidone 2-4 mg/day groups will need to be con-
firmed using randomized controlled studies to establish
their clinical relevance. Additionally, the dropout rates
in studies need to be considered when interpreting the
efficacy findings. Although it is easy to implement the
LOCF methodology, this method may not be the most
robust approach in estimating the true treatment differ-
ences and controlling type I error rates. Also, in this
Table 5 Treatment-emergent adverse events in ≥5% in any active-treatment or placebo groups
Placebo-Adjusted
Difference* ≥2%
Paliperidone
ER
6-12 mg/day
n = 179
n (%)
Placebo
(PALI)
n=9 5
n (%)
Risperidone
2-4 mg/day
n = 113
n (%)
Risperidone
4-6 mg/day
n = 129
n (%)
Placebo
(RIS)
n = 122
n (%)
Paliperidone ER 6-12 mg/day
vs Risperidone
2-4 mg/day
Paliperidone ER 6-12 mg/
day vs Risperidone
4-6 mg/day
Placebo-Adjusted AEs More Common With Paliperidone ER Than Risperidone
Insomnia 26 (14.5) 9 (9.5) 25 (22.1) 22 (17.1) 23
(18.9)
NA
† 5.0
Sinus
tachycardia
14 (7.8) 4 (4.2) 1 (0.9) 2 (1.6) 0 (0.0) 2.7 2.0
Tachycardia 12 (6.7) 3 (3.2) 1 (0.9) 3 (2.3) 0 (0.0) 2.6 NA
†
Placebo-Adjusted AEs More Common With Risperidone Than Paliperidone ER
Somnolence 7 (3.9) 5 (5.3) 10 (8.9) 9 (7.0) 2 (1.6) 7.3 5.4
Restlessness 0 (0.0) 0 (0.0) 9 (8.0) 7 (5.4) 1 (0.8) 7.2 4.6
Nausea 4 (2.2) 4 (4.2) 9 (8.0) 11 (8.5) 4 (3.3) 4.7 5.2
Anxiety 3 (1.7) 2 (2.1) 11 (9.7) 14 (10.9) 7 (5.7) 4.0 5.2
Salivary
hypersecretion
3 (1.7) 0 (0.0) 6 (5.3) 5 (3.9) 0 (0.0) 3.6 2.2
Akathisia 8 (4.5) 3 (3.2) 5 (4.4) 6 (4.7) 1 (0.8) 2.3 2.6
Dizziness 8 (4.5) 3 (3.2) 5 (4.4) 8 (6.2) 3 (2.5) NA
† 2.4
Nasal
congestion
1 (0.6) 0 (0.0) 4 (3.5) 7 (5.4) 3 (2.5) NA
† 2.3
*If Δ ([risperidone-placebo (RIS)] – [paliperidone-placebo (PALI)]) ≥2%. If the placebo rate for any adverse event (AE) was greater than for active treatment, then
active treatment minus placebo was set equal to 0.
†Signifies placebo-adjusted AEs <2%.
All AEs were those reported by week 6.
AE = adverse event; NA = not applicable.
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as is generally found with placebo-controlled trials in
schizophrenia, and long-term effectiveness of these
dosage groups could therefore not be evaluated.
Comparison of risperidone and paliperidone ER pro-
lactin levels was limited by the availability of data and
differences in the timing of specimen collection and trial
duration. Prolactin specimens were collected in only 1
risperidone study (RIS-INT-3) vs all 3 paliperidone ER
trials. The blood samples in the paliperidone ER studies
were obtained at Tmax, whereas the timing of blood
draws was not specified in the risperidone study.
Further, prolactin data for risperidone were available
only at baseline and at week 8 end point, prohibiting
comparisons at the same time point (week 6) between
risperidone and paliperidone ER. However, an analysis
f r o mas e p a r a t e6 - d a yp h a s eIs t u d yi ns t a b l es u b j e c t s
with schizophrenia found similar prolactin pharmacoki-
netic profiles (Cmax and AUC) when subjects received
t h eh i g h e s tr e c o m m e n d e dd o s eo fp a l i p e r i d o n eE R
(12 mg/day) compared with an average dose of risperi-
done (4 mg/day) [2]. Finally, our ability to assess EPS
severity was limited because the studies did not use the
same movement disorder rating scales. With the excep-
tion of spontaneously reported akathisia, EPS-related
AEs (parkinsonism, dystonia, tremor, hypertonia and
hypokinesia) did not meet the criteria specified in the
Methods section (AE differential ≥ 2%), which identified
notable differences in AE rates between paliperidone ER
and risperidone.
Conclusions
In the absence of prospective, randomized, head-to-head
clinical trials, a statistical comparison using propensity
score matching of pooled data may be a feasible and infor-
mative technique to provide a preliminary comparison of
2 medications. This analysis suggests that paliperidone ER
6-12 mg/day may be as efficacious as risperidone 4-6 mg/
day and more efficacious than risperidone 2-4 mg/day.
AE-adjusted incidence rates found differences between the
treatment groups that may be relevant for individual
patients. As this was an indirect analysis of these 2 medi-
cations, randomized, well-controlled, head-to-head studies
are required to confirm these findings.
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